7.160USD-0.14%Mkt Cap: 710.81M USDP/E: —Last update: 2026-06-01
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrop…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap710.81M USD
Enterprise Value363.10M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-174.32M USD
Revenue/Share—
Last Price7.160 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees121
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.81
PEG—
EV/EBITDA-1.86
EV/Revenue—
P/S—
P/B1.93
EPS (TTM)-1.92
EPS (Forward)-1.93
52W Range
3.06571% of range8.866
52W High8.866 USD
52W Low3.065 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-96.84%
ROA-74.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-156.29M USD
CapEx (TTM)1.15M USD
FCF Margin—
FCF Yield-15.61%
Net Debt-360.01M USD
Net Debt/EBITDA1.85
Balance Sheet
Debt/Equity0.12
Current Ratio13.10
Quick Ratio12.57
Book Value/Sh3.802 USD
Cash/Share3.867 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 28, 2022
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)17.00 USD
Target Range11.00 USD – 26.00 USD
# Analysts13
Ownership
Shares Out.98.45M
Float53.74M
Insiders0.82%
Institutions101.69%
Short Interest
Short Ratio8.5d
Short % Float10.64%
Short % Out.9.25%
Shares Short9.10M
Short (prev mo.)9.44M
Technical
SMA 507.425 (-3.6%)
SMA 2006.193 (+15.6%)
Beta2.47
S&P 52W Chg27.70%
Avg Vol (30d)1.01M
Avg Vol (10d)1.16M
Technical Indicators
RSI (14)50.7
MACD-0.1626
MACD Signal-0.1986
MACD Hist.+0.0360
BB Upper7.887 USD
BB Middle7.022 USD
BB Lower6.158 USD
BB Width24.61%
ATR (14)0.4659 USD
Vol Ratio (20d)0.58x